Telmisartan - An effective antihypertensive for 24-hour blood pressure control

Drugs in Context

Volumn 4, Issue 1, 2008, Pages 1-14

  Chambers, Scott ^a   Schachter, Michael ^b   Morrell, Jonathan ^c   Kassianos, George ^a,c   Gaw, Allan ^d   Kirby, Michael ^e   Tamargo, Juan ^f   Yawn, Barbara ^g   Yawn, Roy ^g   Barakat, Khalid ^h   Brown, Pam ^c   Dalrymple, Jamie ^c   Elward, Kurt ^c   Ganiats, Ted ⁱ   Halpin, David ^j   LeFevre, Mike ^k   North, Frederick ^l   Price, David ^m   Rasmussen, Jill ^c   Spann, Steven ⁿ   Stevens, Richard ^c   Tallia, Alfred F ^o   Uden, Don ^p   Waite, Marion ^q   Waller, Derek ^r   more..

^a CSF Medical Communications Ltd   (United Kingdom)

^b NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^c Glasgow Royal Infirmary ^*

^d GLASGOW ROYAL INFIRMARY   (United Kingdom)

^e UNIVERSITY OF HERTFORDSHIRE   (United Kingdom)

^f SCHOOL OF MEDICINE   (Spain)

^g OLMSTED MEDICAL CENTER   (United States)

^h FRIMLEY PARK HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j ROYAL DEVON AND EXETER HOSPITAL   (United Kingdom)

^k UNIVERSITY OF MISSOURI ST LOUIS   (United States)

^l MAYO CLINIC   (United States)

^m UNIVERSITY OF ABERDEEN   (United Kingdom)

ⁿ Houston   (United States)

^o University of Medicine and Dentistry   (United States)

^p UNIVERSITY OF MINNESOTA   (United States)

^q OXFORD BROOKES UNIVERSITY   (United Kingdom)

^r SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

more..

Author keywords

Angiotensin receptor antagonist; Cardiovascular disease; Hypertension; Micardis; Renovascular disease; Telmisartan

Indexed keywords

AMLODIPINE; AMLODIPINE PLUS HYDROCHLOROTHIAZIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; EPROSARTAN; HYDROCHLOROTHIAZIDE; HYDROCHLOROTHIAZIDE PLUS LISINOPRIL; HYDROCHLOROTHIAZIDE PLUS LOSARTAN; HYDROCHLOROTHIAZIDE PLUS TELMISARTAN; HYDROCHLOROTHIAZIDE PLUS VALSARTAN; IRBESARTAN; LISINOPRIL; LOSARTAN; NIFEDIPINE; OLMESARTAN; PERINDOPRIL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PLACEBO; RAMIPRIL; TELMISARTAN; UNCLASSIFIED DRUG; VALSARTAN;

ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BACKACHE; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COUGHING; DIABETIC NEPHROPATHY; DIARRHEA; DIZZINESS; DRUG ABSORPTION; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG PENETRATION; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; EDEMA; EVIDENCE BASED MEDICINE; FATIGUE; FLU LIKE SYNDROME; GERIATRIC PATIENT; HEART LEFT VENTRICLE FAILURE; HIGH RISK POPULATION; HUMAN; HYPERTENSION; HYPOTENSION; KIDNEY FAILURE; MEDLINE; METABOLIC SYNDROME X; MONOTHERAPY; MYALGIA; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; POSTMARKETING SURVEILLANCE; PRURITUS; RECOMMENDED DRUG DOSE; RENAL PROTECTION; SINUSITIS; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION;

EID: 55749104197     PISSN: 17451981     EISSN: 17404398     Source Type: Journal    
DOI: 10.7573/dic.212220     Document Type: Article

References (52)

1. Martina B, Dieterle T, Sigle JP et al. Effects of telmisartan and losartan on left ventricular mass in mild-to-moderate hypertension. A randomized, double-blind trial. Cardiology 2003; 99: 169-70.
2. Cupisti A, Rizza GM, D'Alessandro C et al. Effect of telmisartan on the proteinuria and circadian blood pressure profile in chronic renal patients. Biomed Pharmacother 2003; 57: 169-72.
3. Burnier M, Maillard M. The comparative pharmacology of angiotensin II receptor antagonists. Blood Press Suppl 2001; 1: 6-11.
4. Sharpe M, Jarvis B, Goa KL. Telmisartan: a review of its use in hypertension. Drugs 2001; 61: 1501-29.
5. Israili ZH. Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension. J Hum Hypertens 2000; 14 Suppl 1: S73-86.
6. Maillard MP, Perregaux C, Centeno C et al. In vitro and in vivo characterization of the activity of telmisartan: an insurmountable angiotensin II receptor antagonist. J Pharmacol Exp Ther 2002; 302: 1089-95.
7. Boehringer Ingelheim. Micardis® (telmisartan). Summary of Product Characteristics.
8. Stangier J, Schmid J, Turck D et al. Absorption, metabolism, and excretion of intravenously and orally administered [14C]telmisartan in healthy volunteers. J Clin Pharmacol 2000; 40: 1312-22.
9. Battershall AJ, Scott LJ. Telmisartan. A review of its use in the management of hypertension. Drugs 2006; 66: 51-83.
10. Kurtz TW. Treating the metabolic syndrome: telmisartan as a peroxisome proliferator-activated receptor-gamma activator. Acta Diabetol 2005; 42 Suppl 1: S9-16.
11. Benndorf RA, Rudolph T, Appel D et al. Telmisartan improves insulin sensitivity in nondiabetic patients with essential hypertension. Metabolism 2006; 55: 1159-64.
12. Meredith PA. Optimal dosing characteristics of the angiotensin II receptor antagonist telmisartan. Am J Cardiol 1999; 84: 7K-12K.
13. Kelly-Hayes M, Wolf PA, Kase CS et al. Temporal patterns of stroke onset. The Framingham Study Stroke 1995; 26: 1343-7.
14. Tofler GH, Muller JE, Stone PH et al. Modifiers of timing and possible triggers of acute myocardial infarction in the Thrombolysis in Myocardial Infarction Phase II (TIMI II) Study Group. J Am Coll Cardiol 1992; 20: 1049-55.
15. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med 1997; 157: 2413-46.
16. Neutel J, Smith DH. Evaluation of angiotensin II receptor blockers for 24-hour blood pressure control: meta-analysis of a clinical database. J Clin Hypertens (Greenwich) 2003; 5: 58-63.
17. Smith DH, Cramer MJ, Neutel JM et al. Comparison of telmisartan versus losartan: meta-analysis of titration-to-response studies. Blood Press Monit 2003; 8: 111-7.
18. Mallion J, Siche J, Lacourciere Y. ABPM comparison of the antihypertensive profiles of the selective angiotensin II receptor antagonists telmisartan and losartan in patients with mild-to-moderate hypertension. J Hum Hypertens 1999; 13: 657-64.
19. White WB, Lacourciere Y, Davidai G. Effects of the angiotensin II receptor blockers telmisartan versus valsartan on the circadian variation of blood pressure: impact on the early morning period. Am J Hypertens 2004; 17: 347-53.
20. Calvo C, Hermida RC, Ayala DE, Ruilope LM. Effects of telmisartan 80 mg and valsartan 160 mg on ambulatory blood pressure in patients with essential hypertension. J Hypertens 2004; 22: 837-46.
21. Amerena J, Pappas S, Ouellet JP et al. ABPM comparison of the anti-hypertensive profiles of telmisartan and enalapril in patients with mild-to-moderate essential hypertension. J Int Med Res 2002; 30: 543-52.
22. Neutel JM, Frishman WH, Oparil S et al. Comparison of telmisartan with lisinopril in patients with mild-to-moderate hypertension. Am J Ther 1999; 6: 161-6.
23. Ragot S, Ezzaher A, Meunier A et al. Comparison of trough effect of telmisartan vs perindopril using self blood pressure measurement: EVERESTE study. J Hum Hypertens 2002; 16: 865-73.
24. Williams B, Goose P, Lowe L, Harper R. The prospective, randomized investigation of the safety and efficacy of telmisartan versus ramipril using ambulatory blood pressure monitoring (PRISMA I). J Hypertens 2006; 24: 193-200.
25. Lacourcierc Y, Neutel JM, Davidai G, Koval S. A multicenter, 14-week study of telmisartan and ramipril in patients with mild-to-moderate hypertension using ambulatory blood pressure monitoring. Am J Hypertens 2006; 19: 104-12.
26. Gosse P, Neutel JM, Schumacher H et al. The effect of telmisartan and ramipril on early morning blood pressure surge: a pooled analysis of two randomized clinical trials. Blood Press Monit 2007; 12: 141-147.
27. Freytag F, Schelling A, Meinicke T, Deichsel G. Comparison of 26-week efficacy and tolerability of telmisartan and atenolol, in combination with hydrochlorothiazide as required, in the treatment of mild to moderate hypertension: a randomized, multicenter study. Clin Ther 2001; 23: 108-23.
28. Lacourcierc Y, Lenis J, Orchard R et al. A comparison of the efficacies and duration of action of the angiotensin II receptor blockers telmisartan and amlodipine. Blood Press Monit 1998; 3: 295-302.
29. Lacourciere Y, Martin K. Comparison of a fixed-dose combination of 40 mg telmisartan plus 12.5 mg hydrochlorothiazide with 40 mg telmisartan in the control of mild to moderate hypertension. Am J Ther 2002; 9: 111-7.
30. Freytag F, Holwerda NJ, Karlberg BE et al. Long-term exposure to telmisartan as monotherapy or combination therapy: efficacy and safety. Blood Press 2002; 11: 173-81.
31. Neutel JM, Klein C, Meinicke TW, Schumacher H. Long-term efficacy and tolerability of telmisartan as monotherapy and in combination with other antihypertensive medications. Blood Press 2002; 11: 302-9.
32. Fenton C, Keating GM, Scott LJ. Telmisartan/hydrochlorothiazide: in the treatment of essential hypertension. Drugs 2003; 63: 2013-26; discussion 2027-8.
33. Lacourciere Y, Gil-Extremera B, Mueller O et al. Efficacy and tolerability of fixed-dose combinations of telmisartan plus HCTZ compared with losartan plus HCTZ in patients with essential hypertension. Int J Clin Pract 2003; 57: 273-9.
34. Neutel JM, Littlejohn TW, Chrysant SG, Singh A. Telmisartan/ Hydrochlorothiazide in comparison with losartan/hydrochlorothiazide in managing patients with mild-to-moderate hypertension. Hypertens Res 2005; 28: 555-63.
35. White WB, Giles T, Bakris GL et al. Measuring the efficacy of antihypertensive therapy by ambulatory blond pressure monitoring in the primary care setting. Am Heart J 2006; 151: 176-84.
36. White WB, Weber MA, Davidai G et al. Ambulatory blood pressure monitoring in the primary care setting: assessment of therapy on the circadian variation of blood pressure from the MICCAT-2 Trial. Blood Press Monit 2005; 10: 157-163.
37. Weber MA, White WB, Giles TD et al. An effectiveness study comparing algorithm-based antihypertensive therapy with previous treatments using conventional and ambulatory blood pressure measurements. J Clin Hypertens (Greenwich) 2006; 8: 241-50; quiz 251-2.
38. Neldam S, Edwards C. Telmisartan plus HCTZ vs. amlodipine plus HCTZ in older patients with systolic hypertension: results from a large ambulatory blood pressure monitoring study. Am J Geriatr Cardiol 2006; 15: 151-60.
39. Fogari R, Mugellini A, Zoppi A et al. Effect of telmisartan/ hydrochlorothiazide vs lisinopril/hydrochlorothiazide combination on ambulatory blood pressure and cognitive function in elderly hypertensive patients. J Hum Hypertens 2006; 20: 177-85.
40. Derosa G, Ragonesi PD, Mugellini A et al. Effects of telmisartan compared with eprosartan on blood pressure control, glucose metabolism and lipid profile in hypertensive, type 2 diabetic patients: a randomized, double-blind, placebo-controlled 12-month study. Hypertens Res 2004; 27: 457-64.
41. Sharma AM, Davidson JA, R. GJ, DeSousa NJ. Comparison of the antihypertensive efficacy of telmisartan/hydrochlorothiazide vs valsartan/hydrochlorothiazide in high-risk overweight/obese patients with hypertension and type 2 diabetes. Hypertension 2005; 46: 898. Abstract PC. 11.
42. Barnett AH, Bain SC, Bouter P et al. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 2004; 351: 1952-61.
43. Barnett A. Preventing renal complications in type 2 diabetes: results of the diabetics exposed to telmisartan and enalapril trial.J Am Soc Nephrol 2006; 17: S132-5.
44. Makino H, Haneda M, Babazono T et al. Prevention of transition from incipient to overt nephropathy with telmisartan in patients with type 2 diabetes. Diabetes Care 2007; 30: 1577-8.
45. Bakris G, Burgess E, Weir M, Koval S. Comparative long term effects of two AT1 receptor blockers on proteinuria in patients with type-2 diabetes and overt nephropathy and hypertension: results of the AMADEO trial. Presented at the Annual Meeting of the American Society of Hypertension, Chicago, USA, 19 May 2005.
46. Galle J, Pinnetti S, Wanner C. Antiproteinuric effects of telmisartan versus valsartan in patients with type 2 diabetes and overt nephropathy. Presented at the 21st meeting of the International Society of Hypertension, Fukuoka, Japan. 15-19 October, 2006.
47. Sharma AM, Hollander A, Koster J. Telmisartan in patients with mild/ moderate hypertension and chronic kidney disease. Clin Nephrol 2005; 63: 250-7.
48. Mattioli AV, Bonatti S, Monopoli D et al. Influence of regression of left ventricular hypertrophy on left atrial size and function in patients with moderate hypertension. Blood Press 2005; 14: 273-8.
49. Galzerano D, Tammaro P, del Viscovo L et al. Three-dimensional echocardiographic and magnetic resonance assessment of the effect of telmisartan compared with carvedilol on left ventricular mass a multicenter randomized, longitudinal study. Am J Hypertens 2005; 18: 1563-9.
50. Chrysant SG, Chrysant GS, Desai A. Current status of angiotensin receptor blockers for the treatment of cardiovascular diseases: focus on telmisartan. J Hum Hypertens 2005; 19: 173-83.
51. Sleight P. The ONTARGET/TRANSCEND Trial Programme: baseline data. Acta Diabetol 2005; 42 Suppl 1: S50-6.
52. Diener HC, Sacco R, Yusuf S. Rationale, Design and Baseline Data of a Randomized, Double-Blind, Controlled Trial Comparing Two Antithrombotic Regimens (a Fixed-Dose Combination of Extended-Release Dipyridamole plus ASA with Clopidogrel) and Telmisartan versus Placebo in Patients with Strokes: The Prevention Regimen for Effectively Avoiding Second Strokes Trial (PRoFESS). Cerebrovasc Dis 2007; 23: 368-80.